ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2168

Extramedullary Myelopoiesis Drives Persistent Toll-like Receptor-Mediated Inflammation

Lehn K. Weaver1 and Edward M. Behrens2, 1Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Pediatric Rheumatology, Childrens Hospital of Philadelphia, Philadelphia, PA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Hematopoietic stem cells, Inflammation, interleukins (IL), monocytes and toll-like receptors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Innate Immunity and Rheumatic Disease: Mediators, Cells and Receptors

Session Type: Abstract Submissions (ACR)

Background/Purpose: Many rheumatic diseases are driven by chronic, repeated activation of Toll-like receptors (TLR) causing the initiation and perpetuation of disease. However, TLR-activated innate immune cells undergo the well-known immunoregulatory phenomenon of TLR tolerance, whereby the initial activation of TLRs results in impaired proinflammatory responses to subsequent TLR stimuli. Therefore, it is unclear how TLR-driven inflammation persists in vivo. Our well-characterized model of repeated TLR9-driven inflammation demonstrates that repeated activation of TLR9 results in a feed-forward, interleukin (IL)-12-mediated inflammatory response culminating in systemic immunopathology rather than tolerance. Using this model, we dissect the cellular mechanisms utilized to bypass TLR9 tolerance in vivo.

Methods: In vitro mixed TLR9 sufficient and deficient cell cultures were stimulated with CpG1826, a TLR9 agonist, to demonstrate that IL-12 is a readout of cell-intrinsic TLR9 activation. Yet40 IL-12-reporter mice were treated with 4 doses of CpG1826 before tissue leukocytes were isolated and analyzed by flow cytometry to identify the IL-12-producing cells. Bone marrow, peripheral blood, and tissue leukocytes from CpG-treated mice were stained for myeloid progentor cell markers to determine if myelopoiesis is altered during TLR9-mediated systemic inflammation.

Results: We demonstrate that inflammatory monocyte-derived dendritic cells increase in frequency and total numbers during TLR9-mediated systemic inflammation, and are the key IL-12-producing cell in this model. To determine the origin of these inflammatory tissue-invading cells, we tested peripheral blood and bone marrow of CpG-treated mice to enumerate the number of inflammatory monocytes and myeloid progenitor cells. To our surprise, the total number of peripheral blood inflammatory monocytes and bone marrow myeloid precursors was unchanged during TLR9-induced systemic inflammation. In contrast, extramedullary myeloid precursors were markedly increased in peripherally inflamed tissues of CpG-treated mice.

Conclusion: Our data highlight an important mechanism whereby persistent TLR9 activation bypasses TLR tolerance in vivo by increasing extramedullary myelopoiesis. Increased extramedullary myelopoiesis provides a continuous source of new TLR9-responsive cells that perpetuates TLR-driven inflammation. These new insights into the mechanisms driving persistent TLR-mediated inflammation may lead to novel therapeutic targets to ameliorate TLR9-mediated rheumatic diseases by intervening to suppress TLR-driven extramedullary myelopoiesis.


Disclosure:

L. K. Weaver,
None;

E. M. Behrens,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/extramedullary-myelopoiesis-drives-persistent-toll-like-receptor-mediated-inflammation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology